Proactive Investors - Run By Investors For Investors

Imugene has cancer vaccine trial data published in prestigious medical journal

Imugene is an Australian biotechnology company developing cancer immunotherapies, with operations in the U.S. and in Europe.
cancer cells
The company’s key assets are B-cell peptide cancer vaccines

Imugene Ltd’s (ASX:IMU) phase 1 clinical trial data for its B cell peptide cancer vaccine B-Vaxx has been published in the prestigious American Association for Cancer Research journal Clinical Cancer Research.

The title of the article is "Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors."

The article is primarily authored by Imugene’s Scientific Advisory Board members Professor Pravin Kaumaya from the Ohio State University and Dr Tanios Bekaii-Saab from the Mayo Clinic.


Notably, this first-in-human phase 1 study evaluated the safety profile, optimal immunologic/biologic dose and immunogenicity of the combination of two peptide B-cell epitope vaccines engineered to represent the trastuzumab and pertuzumab HER-2 binding sites.

While the billion dollar blockbusters marketed by Roche/Genentech Herceptinâ and Perjetaâ have been approved for clinical use, patients often develop resistance to these therapies.

READ: Imugene targets defender B-cells with cancer vaccines HER-Vaxx and B-Vaxx

Professor Pravin Kaumaya said: “We have advanced a new paradigm in immunotherapy that focuses on humoral responses based on conformational B-cell epitope vaccines.

“The study vaccine is safe, exhibits anti-tumor activity and shows preliminary indications that peptide vaccination may avoid therapeutic resistance and offers a promising alternative to monoclonal antibody therapies.”

Two lead cancer vaccine candidates

The company’s key assets are B-lymphocyte or B-cell peptide cancer vaccines that link an immunogenic protein with a B-cell epitope peptide and include an adjuvant to induce the body into producing antibodies against normal self-proteins.

Imugene’s two lead therapeutic vaccine candidates are the HER-Vaxx vaccine and the B-Vaxx vaccine.

HER-Vaxx is an anti-HER2/neu product that has been taken through a successful phase 1b study in 14 gastric cancer patients.

B-Vaxx is also another B-cell peptide cancer vaccine and is designed to treat tumours that over-express the HER2/neu receptor.

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
knee physio
February 18 2019
Results from an eight-year clinical extension study showed that ChondroMimetic was able to regenerate cartilage to a structural quality almost identical to native cartilage
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use